Precipio, Inc. (PRPO): Price and Financial Metrics

Precipio, Inc. (PRPO): $0.80

-0.05 (-6.21%)

POWR Rating

Component Grades













Add PRPO to Watchlist
Sign Up

Industry: Biotech



in industry

PRPO Stock Summary

  • With a market capitalization of $18,825,817, PRECIPIO INC has a greater market value than merely 6.24% of US stocks.
  • Of note is the ratio of PRECIPIO INC's sales and general administrative expense to its total operating expenses; 86.6% of US stocks have a lower such ratio.
  • For PRPO, its debt to operating expenses ratio is greater than that reported by only 14.16% of US equities we're observing.
  • Stocks that are quantitatively similar to PRPO, based on their financial statements, market capitalization, and price volatility, are OPRX, LEV, ASLE, XOMA, and WNS.
  • PRPO's SEC filings can be seen here. And to visit PRECIPIO INC's official web site, go to

PRPO Valuation Summary

  • PRPO's EV/EBIT ratio is -1.1; this is 113.75% lower than that of the median Healthcare stock.
  • Over the past 243 months, PRPO's EV/EBIT ratio has gone up 5.9.

Below are key valuation metrics over time for PRPO.

Stock Date P/S P/B P/E EV/EBIT
PRPO 2022-09-23 1.9 0.9 -1.6 -1.1
PRPO 2022-09-22 2.0 0.9 -1.8 -1.2
PRPO 2022-09-21 2.1 1.0 -1.9 -1.3
PRPO 2022-09-20 2.2 1.0 -2.0 -1.4
PRPO 2022-09-19 2.4 1.1 -2.1 -1.5
PRPO 2022-09-16 2.3 1.0 -2.0 -1.4

PRPO Growth Metrics

    Its year over year price growth rate is now at -74.75%.
  • Its 3 year net income to common stockholders growth rate is now at 25.28%.
  • Its 4 year net cashflow from operations growth rate is now at -35.67%.
Over the past 15 months, PRPO's revenue has gone up $2,787,000.

The table below shows PRPO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 9.487 -7.509 -10.799
2022-03-31 9.472 -7.622 -11.668
2021-12-31 8.849 -6.577 -8.53
2021-09-30 8.355 -6.628 -8.194
2021-06-30 7.736 -6.92 -9.636
2021-03-31 6.7 -7.134 -8.872

PRPO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRPO has a Quality Grade of D, ranking ahead of 7.61% of graded US stocks.
  • PRPO's asset turnover comes in at 0.324 -- ranking 58th of 76 Measuring and Control Equipment stocks.
  • ROP, AXDX, and TMO are the stocks whose asset turnover ratios are most correlated with PRPO.

The table below shows PRPO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.324 0.268 19.897
2021-03-31 0.331 0.223 15.583
2020-12-31 0.307 0.189 14.223
2020-09-30 0.247 0.135 15.678
2020-06-30 0.200 0.076 11.555
2020-03-31 0.174 0.084 12.523

PRPO Price Target

For more insight on analysts targets of PRPO, see our PRPO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.5 (Moderate Buy)

PRPO Stock Price Chart Interactive Chart >

Price chart for PRPO

PRPO Price/Volume Stats

Current price $0.80 52-week high $2.83
Prev. close $0.86 52-week low $0.77
Day low $0.80 Volume 36,691
Day high $0.86 Avg. volume 203,272
50-day MA $1.17 Dividend yield N/A
200-day MA $1.26 Market Cap 18.28M

Precipio, Inc. (PRPO) Company Bio

Precipio, Inc. operates as a biotechnology company. The Company offers medicines for oncology, cardiology, neurology, and inherited diseases. Precipio also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Precipio serves customers in the United States.

PRPO Latest News Stream

Event/Time News Detail
Loading, please wait...

PRPO Latest Social Stream

Loading social stream, please wait...

View Full PRPO Social Stream

Latest PRPO News From Around the Web

Below are the latest news stories about PRECIPIO INC that investors may wish to consider to help them evaluate PRPO as an investment opportunity.

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

Adding customer segment exceeding $100M in market potentialNEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage, this distribution channel partner’s sales team will begin promoting and driving sales of the HemeScreen platform

Yahoo | September 15, 2022

Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

Precipio continues to build strong team in anticipation of substantial growth in the next 12 monthsNEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (a

Yahoo | August 24, 2022

Precipio (PRPO) Gets a Buy from Maxim Group

E ratio of -2.82.

Christine Brown on TipRanks | August 17, 2022

Precipio Launches New 1-Step Technology for all HemeScreen Assays

New technology enables same day test results by eliminating extra confirmation stepNEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s customers using HemeScreen in their laboratory will have the option of upgrading to the 1-step assay, or remaining with the current assay. While the first generation of panels required a 2-step process that included a

Yahoo | August 16, 2022

Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development

Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributorsNEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Toni-Ann Mills as the Company’s Senior Director for Learning & Development. With a ~$0.5B market potential for HemeScreen, Precipio is preparing to mobilize all resources towards capturing significant market share. As Precipio

Yahoo | August 10, 2022

Read More 'PRPO' Stories Here

PRPO Price Returns

1-mo -32.20%
3-mo -27.93%
6-mo -42.03%
1-year -71.63%
3-year -67.35%
5-year -97.53%
YTD -49.37%
2021 -23.67%
2020 0.98%
2019 -8.89%
2018 -87.50%
2017 -85.71%

Continue Researching PRPO

Want to see what other sources are saying about Precipio Inc's financials and stock price? Try the links below:

Precipio Inc (PRPO) Stock Price | Nasdaq
Precipio Inc (PRPO) Stock Quote, History and News - Yahoo Finance
Precipio Inc (PRPO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4242 seconds.